

**Facsimile**

Please deliver to Examiner immediately.

RECEIVED
CENTRAL FAX CENTER
NOV 29 2004

Date: November 29, 2004

Fax No.: 703-872-9306

To: Examiner Raymond J. Henley III

Art Unit: 1614

Appln. No.: 10/627,198

Filing Date: 07/25/2003

Docket No.: Z70606-2 US

From: Karen Cochran

No. of Pages:
(including this one) 8

If transmission is not complete or is illegible, please contact me at 302-886-4836

Certificate of Transmission under 37 CFR 1.8

I hereby certify that the following correspondence is being facsimile transmitted to the United States Patent and Trademark office on:

Fran Toutkaldjian
Typed or Printed Name


Signature

Attachments

- 1) Response to Non-Compliant Second preliminary Amendment

Information contained in this fax may be confidential and/or legally privileged. This fax is intended to be reviewed initially by only the individual or legal entity named above. If the reader of this transmittal page is not the intended recipient or a representative of the intended recipient, you are hereby notified that any reading, dissemination or copying of this fax or the information contained herein is prohibited. If you have received this fax in error please immediately notify the sender by telephone and return this fax to the sender at the address below. Thank you.

AstraZeneca
Global Intellectual Property
1800 Concord Pike
Wilmington DE-19850-5437

Tel: +1 302 886 3000
Fax: +1 302 886 8221
www.astrazeneca-us.com

AstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, Delaware 19850-5438
USA

CERTIFICATE OF TRANSMISSION 37 CFR 1.8

I hereby certify that the attached papers or fee are being Transmitted to the United States Patent Office on November 29, 2004 to fax number 703-872-9306.

11/29/04

(Date)

Fran Toukaldjian

(Printed Name)



(Signature)

DOCKET NO.: Z70606-2 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Daniel Boyd Brown**Application No.: **10/627,198**Group Art Unit: **Not yet assigned**Filed: **July 25, 2003**Examiner: **Not yet assigned**For: **Quetiapine Granules**RECEIVED
CENTRAL FAX CENTER

NOV 29 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Applicants hereby respond to the Notice of Non-Compliant Amendment dated October 29, 2004 for the above-identified patent application.

Amendments comply with 37 CFR 1.121 requirements are listed below.

Amendments to the Specification are described on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks begin on page 7 of this paper.